Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

• DOI: 10.1186/s12885-015-1267-0
• Publication Date: 2015-04-11T04:05:41Z
• Authors: Hua Gao; Fei Wang; Xiaolei Lan; Chuzhong Li; Jie Feng; Jiwei Bai; Lei Cao; Songbai Gui; Lichuan Hong; Yazhuo Zhang
• Keywords: Prolactinoma; Pituitary Tumors

Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account 25–30% of functioning pituitary adenomas, and bromocriptine (BRC) is only commercially available DAs in China. However, tumors resistant to therapy 5–18% patients. The exomes six responsive prolactinomas were analyzed by whole-exome sequencing. Using stringent variant calling filtering parameters, ten somatic variants that mainly associated with DNA repair or protein metabolic processes identified. New identified multiple genes including PRDM2, PRG4, MUC4, DSPP, DPCR1, RP1L1, MX2, POTEF, C1orf170, KRTAP10-3. expression these was then quantified real-time reverse-transcription PCR (RT–qPCR) 12 3 normal glands. mRNA levels PRDM2 approximately five-fold lower than (p < 0.05). tumors, as determined Western blotting immunohistochemical analysis Overexpression upregulated dopamine receptor D2 (D2DR) inhibited phosphorylation ERK1/2 MMQ cells. showed a synergistic effect BRC on inhibition prolactin (PRL) secretion cell viability, low tumor recurrence. downregulation may play role dopamine-agonist resistance recurrence prolactinomas.